The Effects of Sub-Chronic Treatment with Pioglitazone on the Septic Mice Mortality in the Model of Cecal Ligation and Puncture: Involvement of Nitric Oxide Pathway
Sepsis is a systemic inflammatory response syndrome caused by an infection and remains as a major challenge in health care. Many studies have reported that pioglitazone may display anti-inflammatory effects. This study was designed to evaluate the effect of subchronic treatment with pioglitazone on high-grade septic mice survival and nitrergic system involvement. Diffused sepsis was induced by cecal ligation and puncture (CLP) surgery in male NMRI mice (20-30 g). Pioglitazone (5,10 and 20 mg/kg) was administered by gavage daily for 5 days prior to surgery. Nitric oxide involvement was assessed by sub-chronic administration of a non-selective nitric oxide synthase inhibitor, L-NAME and a selective inducible nitric oxide synthase inhibitor, aminoguanidine. TNF-α and IL-1β plasma levels were measured by ELISA. Pioglitazone (10 and 20 mg/kg) significantly improved survival rate in septic mice. The chronic intraperitoneally co-administration of L-NAME (0.5 mg/kg, daily) or aminoguanidine (1 mg/kg, daily) with a daily dose of pioglitazone, 5 mg/kg, significantly increased the survival rate. This survival improving effect was accompanied by a significant reduction in pro-inflammatory cytokines TNF-α and IL-1β plasma levels. In conclusion, sub-chronic pioglitazone treatment can improve survival in mouse sepsis model by CLP. Inhibition of nitric oxide release, probably through inducible nitric oxide synthase at least in part is responsible for this effect. Suppression of TNF-α and IL-1β could be another mechanism in pioglitazone-induced survival improving effect in septic mice.
Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29(7):1303-10.
Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003;348(2):138-50.
Ignarro LJ. A novel signal transduction mechanism for transcellular communication. Hypertension 1990;16(5):477-83.
Titheradge MA. Nitric oxide in septic shock. Biochim Biophys Acta 1999;1411(2-3):437-55.
Connelly L, Palacios-Callender M, Ameixa C, et al. Biphasic regulation of NF-kappa B activity underlies the pro- and anti-inflammatory actions of nitric oxide. J Immunol 2001;166(6):3873-81.
Cobb JP, Hotchkiss RS, Swanson PE, et al. Inducible nitric oxide synthase (iNOS) gene deficiency increases the mortality of sepsis in mice. Surgery 1999;126(2):438-42.
Sessa WC. The nitric oxide synthase family of proteins. J Vasc Res 1994;31(3):131-43.
Rosselet A, Feihl F, Markert M, et al. Selective iNOS inhibition is superior to norepinephrine in the treatment of rat endotoxic shock. Am J Respir Crit Care Med 1998;157(1):162-70.
Liu SF, Adcock IM, Old RW, et al. Differential regulation of the constitutive and inducible nitric oxide synthase mRNA by lipopolysaccharide treatment in vivo in the rat. Crit Care Med 1996;24(7):1219-25.
Ketteler M, Cetto C, Kirdorf M, et al. Nitric oxide in= sepsis-syndrome: potential treatment of septic shock by nitric oxide synthase antagonists. Kidney Int Suppl 1998;64:S27-30.
Shapiro L, Gelfand JA. Cytokines and sepsis: pathophysiology and therapy. New Horiz 1993;1(1):13-22.
Misko TP, Moore WM, Kasten TP, et al. Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur J Pharmacol 1993;233(1):119-25.
Wright CE, Rees DD, Moncada S. Protective and pathological roles of nitric oxide in endotoxin shock. Cardiovasc Res 1992;26(1):48-57.
Xie XQ, Shinozawa Y, Sasaki J, et al. The effects of arginine and selective inducible nitric oxide synthase inhibitor on the pathophysiology of sepsis in a CLP model. J Surg Res 2008;146(2):298-303.
Delerive P, Fruchart JC, Staels B. Peroxisome proliferatoractivated receptors in inflammation control. J Endocrinol 2001;169(3):453-9.
Schmidt MV, Brüne B, von Knethen A. The nuclear hormone receptor PPARγ as a therapeutic target in major diseases. ScientificWorldJournal 2010;10:2181-97.
Dehmer T, Heneka MT, Sastre M, et al. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem 2004;88(2):494-501.
Zingarelli B, Sheehan M, Hake PW, et al. Peroxisome proliferator activator receptor-gamma ligands, 15-deoxy- Delta(12,14)-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways. J Immunol= 2003;171(12):6827-37.
Clark RB. The role of PPARs in inflammation and immunity. J Leukoc Biol 2002;71(3):388-400.
Wichterman KA, Baue AE, Chaudry IH. Sepsis and septic shock--a review of laboratory models and a proposal. J Surg Res 1980;29(2):189-201.
Moezi L, Heidari R, Amirghofran Z, et al. Enhanced antiulcer effect of pioglitazone on gastric ulcers in cirrhotic rats: the role of nitric oxide and IL-1β. Pharmacol Rep 2013;65(1):134-43.
Shafaroodi H, Moezi L, Ghorbani H, et al. Sub-chronic treatment with pioglitazone exerts anti-convulsant effects in pentylenetetrazole-induced seizures of mice: The role of nitric oxide. Brain Res Bull 2012;87(6):544-50.
Auwerx J. PPARgamma, the ultimate thrifty gene. Diabetologia 1999;42(9):1033-49.
Willson TM, Lambert MH, Kliewer SA. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem 2001;70:341-67.
Shiojiri T, Wada K, Nakajima A, et al. PPARgamma ligands inhibit nitrotyrosine formation and inflammatory mediator expressions in adjuvant-inducedrheumatoid arthritis mice. Eur J Pharmacol 2002;448(2-3):231-8.
Woerly G, Honda K, Loyens M, et al. Peroxisome proliferator-activated receptors alpha and gamma downregulate allergic inflammation and eosinophil activation. J Exp Med 2003;198(3):411-21.
Ueki S, Matsuwaki Y, Kayaba H, et al. Peroxisome proliferator-activated receptor gamma regulates eosinophil functions: a new therapeutic target for allergic airway inflammation. Int Arch Allergy Immunol 2004;134(Suppl1):30-6.
Katayama K, Wada K, Nakajima A, et al. A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model. Gastroenterology 2003;124(5):1315-24.
Neve BP, Fruchart JC, Staels B. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem Pharmacol 2000;60(8):1245-50.
Zhang HL, Xu M, Wei C, et al. Neuroprotective effects of pioglitazone in a rat model of permanent focal cerebral ischemia are associated with peroxisome proliferatoractivated receptor gamma-mediated suppression of nuclear factor-κB signaling pathway. Neuroscience 2011;176:381-95.
von Knethen A, Soller M, Brüne B. Peroxisome proliferator-activated receptor gamma (PPAR gamma) and sepsis. Arch Immunol Ther Exp (Warsz) 2007;55(1):19-25.
Tsujimura Y, Matsutani T, Matsuda A, et al. Effects of pioglitazone on survival and omental adipocyte function in mice with sepsis induced by cecal ligationand puncture. J Surg Res 2011;171(2):e215-21.
Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004;351(11):1106-18.
Belvisi MG, Hele DJ, Birrell MA. Peroxisome proliferatoractivated receptor gamma agonists as therapy for chronic airway inflammation. Eur J Pharmacol 2006;533(1-3):101-9.
Ivashchenko CY, Duan SZ, Usher MG, et al. PPARgammaknockout in pancreatic epithelial cells abolishes the inhibitory effect of rosiglitazone on caerulein-induced acute pancreatitis. Am J Physiol Gastrointest Liver Physiol 2007;293(1):G319-26.
Cuzzocrea S, Pisano B, Dugo L, et al. Rosiglitazone, a ligand of the peroxisome proliferator-activated receptorgamma, reduces acute inflammation. Eur J Pharmacol 2004;483(1):79-93.
Demerjian M, Man MQ, Choi EH, et al. Topical treatment with thiazolidinediones, activators of peroxisome proliferator-activated receptor-gamma, normalizes epidermal homeostasis in a murine hyperproliferative disease model. Exp Dermatol 2006;15(3):154-60.
Ishibashi M, Egashira K, Hiasa K, et al. Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 2002;40(5):687-93.
Haraguchi G, Kosuge H, Maejima Y, et al. Pioglitazone reduces systematic inflammation and improves mortality in apolipoprotein E knockout mice with sepsis. Intensive Care Med 2008;34(7):1304-12.
Araújo CV, Estato V, Tibiriçá E, et al. PPAR gamma activation protects the brain against microvascular dysfunction in sepsis. Microvasc Res 2012;84(2):218-21.
Zingarelli B, Cook JA. Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation. Shock 2005;23(5):393-9.
Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998;391(6662):82-6.
Ricote M, Li AC, Willson TM, et al. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998;391(6662):79-82.
Feihl F, Waeber B, Liaudet L. Is nitric oxide overproduction the target of choice for the management of septic shock? Pharmacol Ther 2001;91(3):179-213.
Araújo AV, Ferezin CZ, Pereira Ade C, et al. Augmented nitric oxide production and up-regulation of endothelial nitric oxide synthase during cecal ligation and perforation. Nitric Oxide 2012;27(1):59-66.
Bucher M, Ittner KP, Zimmermann M, et al. Nitric oxide synthase isoform III gene expression in rat liver is upregulated by lipopolysaccharide and lipoteichoic acid. FEBS Lett 1997;412(3):511-4.
Price S, Mitchell JA, Anning PB, et al. Type II nitric oxide synthase activity is cardio-protective in experimental sepsis. Eur J Pharmacol 2003;472(1-2):111-8.
Gianotti L, Alexander JW, Pyle T, et al. Argininesupplemented diets improve survival in gutderived sepsis and peritonitis by modulating bacterial clearance: the role of nitric oxide. Ann Surg 1993;217:644-54.
Goya K, Sumitani S, Otsuki M, et al. The thiazolidinedione drug troglitazone up-regulates nitric oxide synthase expression in vascular endothelial cells. J Diabetes Complications 2006;20(5):336-42.
Huang PH, Sata M, Nishimatsu H, et al. Pioglitazone ameliorates endothelial dysfunction and restores ischemiainduced angiogenesis in diabetic mice. Biomed Pharmacother 2008;62(1):46-52.
Adabi Mohazab R, Javadi-Paydar M, Delfan B, et al. Possible involvement of PPAR-gamma receptor and nitric oxide pathway in the anticonvulsant effect of acute pioglitazone on pentylenetetrazole-induced seizures in mice. Epilepsy Res 2012;101(1-2):28-35.
Babaei R, Javadi-Paydar M, Sharifian M, et al. Involvement of nitric oxide in pioglitazone memory improvement in morphine-induced memory impaired mice. Pharmacol Biochem Behav 2012;103(2):313-21.
Konturek PC, Brzozowski T, Kania J, et al. Pioglitazone, a specific ligand of peroxisome proliferator-activated receptor-gamma, accelerates gastric ulcer healing in rat. Eur J Pharmacol 2003;472(3):213-20.
Ferreira AE, Sisti F, Sônego F, et al. PPAR-γ/IL 10 axis inhibits MyD88 expression and ameliorates murine polymicrobial sepsis. J Immunol 2014;192(5):2357-65.
Kutsukake M, Matsutani T, Tamura K, et al. Pioglitazone attenuates lung injury by modulating adipose inflammation. J Surg Res 2014;189(2):295-303.
|Issue||Vol 53, No 10 (2015)|
|Sepsis Pioglitazone Nitric oxide Cecal ligation and puncture Cytokines Mice|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|